HCV - AVI BioPharma in Chiron licensing deal

AVI BioPharma in Chiron licensing deal
BusinessWeek - JAN. 27 11:51 A.M. ET AVI BioPharma Inc., a biopharmaceutical company, said Friday Chiron Corp. granted AVI a nonexclusive license to Chiron's patents for hepatitis C virus, or HCV, antisense therapeutics drugs. Chronic HCV infection causes liver

SuperGen to buy Montigen Inc.
Contra Costa Times - SuperGen to buy Montigen Inc. SuperGen Inc. (SUPG) said it agreed to acquire privately held oncology drug developer Montigen Pharmaceuticals Inc. for $18 million in cash and stock. Under the terms of the agreement, Dublin-based SuperGen will pay

Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration
RxPG - "The initial success of our efforts to accelerate the HCV clinical trial program for Tarvacin Anti-Viral is gratifying in view of Tarvacin's promise as an important new treatment option for a number of viral infections, including chronic hepatitis C

Inovio Biomedical to Develop Vaccine for Hepatitis C in Partnership
Genetic Engineering News - Inovio Biomedical Corporation (AMEX:INO), a late stage developer of cancer and other therapies using electroporation to deliver drugs and nucleic acids, announced today that it has signed an agreement with Swedish-based Tripep AB (The Stockholm